CD8A and neoplasm: However, there was at least a doubling of percent lymphocytes in tumors from mice treated with the G100–ZVex combination (Supplementary Fig. 5a), suggesting, at least in this case, the overall increase in antigen-specific CD8 T cells was sufficient to overcome a stagnant CD8:Treg ratio and achieve significant anti-tumor control.